Business Context and Reporting Period
This Form 6-K is filed by Midatech Pharma PLC (noted as Biodexa Pharmaceuticals Plc in metadata) for the month of May 2020, with a specific filing date of May 12, 2020. The registrant is a foreign private issuer headquartered in Cardiff, United Kingdom, and files annual reports on Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of a corporate event rather than a financial statement.
Material Changes
The primary material change disclosed is the submission of a press release (Exhibit 99.1) dated May 12, 2020, titled "Amendment to Relationship Agreement." The filing incorporates this press release by reference into the Company's Registration Statement on Form F-3 (File No. 333-233901).
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the announcement of the amended relationship agreement.
Key Facts for Investor Verification
- Verify the specific terms of the "Amendment to Relationship Agreement" detailed in the attached press release (Exhibit 99.1), as the summary text does not contain the agreement's details.
- Confirm the impact of this amendment on the Company's Registration Statement on Form F-3 (File No. 333-233901).
- Note that no financial performance data is included in this specific filing.